NASDAQ:CTNM Contineum Therapeutics (CTNM) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free CTNM Stock Alerts $15.69 +0.88 (+5.94%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$14.67▼$15.8550-Day Range N/A52-Week Range$13.27▼$16.06Volume114,051 shsAverage Volume85,437 shsMarket Capitalization$286.44 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsSocial Media Get Contineum Therapeutics alerts: Email Address Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Contineum TherapeuticsContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Read More CTNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTNM Stock News HeadlinesMay 8, 2024 | americanbankingnews.comContineum Therapeutics, Inc.'s (NASDAQ:CTNM) Quiet Period Will Expire on May 15thMay 2, 2024 | finance.yahoo.comContineum Therapeutics Announces Pricing of Initial Public OfferingMay 9, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 1, 2024 | americanbankingnews.comContineum Therapeutics (NASDAQ:CTNM) Now Covered by Analysts at Stifel NicolausMay 1, 2024 | americanbankingnews.comContineum Therapeutics (NASDAQ:CTNM) Receives New Coverage from Analysts at Royal Bank of CanadaMay 1, 2024 | americanbankingnews.comContineum Therapeutics (NASDAQ:CTNM) Receives New Coverage from Analysts at Morgan StanleySee More Headlines Receive CTNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTNM CUSIPN/A CIK1855175 Webwww.contineum-tx.com Phone(858) 333-5280FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$28.00 High Stock Price Target$30.00 Low Stock Price Target$25.00 Potential Upside/Downside+78.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$50 million Price / Sales5.73 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares18,256,000Free FloatN/AMarket Cap$286.44 million OptionableN/A BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Carmine N. Stengone MBA (Age 48)MS, President, CEO, Secretary & Director Comp: $790.3kMr. Peter T. Slover CPA (Age 49)Chief Financial Officer Comp: $569.7kDr. Daniel S. Lorrain Ph.D. (Age 55)Chief Science Officer Comp: $565.02kDr. Stephen L. Huhn F.A.A.P (Age 63)F.A.C.S., M.D., Chief Medical Officer & Senior VP of Clinical Development Mr. Austin Chen Ph.D.SVP & Head of ResearchMr. Michael MayberrySenior Director & Corporate ControllerMore ExecutivesKey CompetitorsAkebia TherapeuticsNASDAQ:AKBAVanda PharmaceuticalsNASDAQ:VNDAXeris BiopharmaNASDAQ:XERSWerewolf TherapeuticsNASDAQ:HOWLVerastemNASDAQ:VSTMView All Competitors CTNM Stock Analysis - Frequently Asked Questions Should I buy or sell Contineum Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Contineum Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTNM shares. View CTNM analyst ratings or view top-rated stocks. What is Contineum Therapeutics' stock price target for 2024? 3 equities research analysts have issued twelve-month target prices for Contineum Therapeutics' shares. Their CTNM share price targets range from $25.00 to $30.00. On average, they predict the company's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 78.5% from the stock's current price. View analysts price targets for CTNM or view top-rated stocks among Wall Street analysts. How have CTNM shares performed in 2024? Contineum Therapeutics' stock was trading at $15.40 at the start of the year. Since then, CTNM stock has increased by 1.9% and is now trading at $15.69. View the best growth stocks for 2024 here. When did Contineum Therapeutics IPO? Contineum Therapeutics (CTNM) raised $110 million in an initial public offering on Friday, April 5th 2024. The company issued 6,875,000 shares at a price of $16.00 per share. When does the company's quiet period expire? Contineum Therapeutics' quiet period expires on Wednesday, May 15th. Contineum Therapeutics had issued 6,875,000 shares in its public offering on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Contineum Therapeutics? Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTNM) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.